Itoco

Dorzolamide, the active ingredient in Itoco, is a carbonic anhydrase inhibitor presented as a topical ophthalmic solution for ocular use. It lowers intra‑ocular pressure in patients with open‑angle glaucoma or ocular hypertension.

GNH USA supplies Itoco as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Dorzolamide acts on the ocular fluid‑production pathway to reduce intra‑ocular pressure in glaucoma‑related conditions.

Open‑angle glaucoma: reduces intra‑ocular pressure to help prevent optic nerve damage. Ocular hypertension: lowers eye pressure to reduce the risk of developing glaucoma.

Adverse reactions are generally related to local ocular irritation or systemic hypersensitivity.

Common Side Effects: - Burning or stinging sensation in the eye - Blurred vision after instillation - Unpleasant taste sensation - Conjunctival hyperemia (redness) - Foreign body sensation - Mild eye discomfort

Serious or Rare Side Effects: - Severe allergic reactions such as Stevens‑Johnson syndrome - Corneal edema or ulceration - Granulomatous inflammation of the eyelid - Persistent ocular pain - Vision loss - Systemic sulfonamide hypersensitivity

Before using Itoco, consider the following safety measures.

Monitor intra‑ocular pressure regularly: ensure therapeutic effectiveness. Assess sulfonamide allergy history: avoid if hypersensitivity is known. Avoid use in severe corneal disease: may exacerbate condition. Do not combine with other carbonic anhydrase inhibitor eye drops without medical supervision: risk of excessive pressure reduction. Store at room temperature: keep in the original container, protect from light and moisture.

Dorzolamide may interact with other ocular or systemic medications.

Major Interactions (Avoid): - Concurrent use with other carbonic anhydrase inhibitor eye drops (e.g., brinzolamide) may cause additive pressure‑lowering effects. - Systemic sulfonamides may increase risk of hypersensitivity reactions. - Combination with topical ocular anesthetics may heighten corneal toxicity.

Moderate Interactions (Monitor Closely): - Beta‑blocker eye drops may produce additive intra‑ocular pressure reduction. - Systemic carbonic anhydrase inhibitors (e.g., acetazolamide) may increase systemic side effects. - Use with prostaglandin analogues may require IOP monitoring for synergistic effect.